ACTRN12613000339752招募中2 期
A Single Centre Phase II Study Of the safety and efficacy of Haematopoietic Stem Cell Transplantation For Severe Auto-Immune Diseases.
St Vincent's Hospital, Sydney0 个研究点目标入组 150 人开始时间: 2013年3月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Adequate organ function as measured by:
- •Cardiac LV Ejection Fraction greater than 45%, total Lung Capacity greater than 60%, Pulmonary artery pressure greater than 50mmHg, DLCO greater than or equal to 50%.
- •Negative serology for HBV, HCV and HIV.
- •Negative pregnancy test.
- •Able to provide informed consent and the absence of mental and cognitive deficits which can interfere with the capability of providing the informed consent.
- •Absence of severe chronic infection.
- •Severe auto-immune disease less than 7 years duration (excluding Multiple Sclerosis) OR Multiple sclerosis of any duration unresponsive to multiple standard therapies including corticosteroids.
- •HSCT deemed best high-intensity immunotherapeutic treatment in the opinion of the referring physician.
- •Sperm collection or ova cryopreservation is to be offered prior to HSCT in those of child-bearing age
- •Specific Inclusion Criteria for each disease:
- •1.Systemic Sclerosis:
- •Early, rapidly progressive inflammatory diffuse scleroderma with truncal skin involvement and/or involving lungs and/or heart (myocarditis) which has failed to stabilize with anti-rheumatic agents. All patients with severe Systemic Sclerosis will undergo right catheterisation prior to cyclophosphamide mobilisation to assess for pulmonary artery pressure. Ideally patients will also have signs of ongoing disease-related inflammation immediately prior to ASCT. Early disease is defined as disease in which the timing from second symptom onset to ASCT was 7 years or less
- •2. Systemic lupus erythematosus (SLE):
- •Diagnosis according to ACR-criteria with antinuclear antibodies positive on at least two successive tests at three months interval plus disease duration less than 7 years since the diagnosis or first time of intensive immunosuppressive drugs. Unresponsive to multiple therapies including at least 6 months of the best standard local therapy using prednisone, intravenous cyclophosphamide or mycophenolate mofetil either alone or successively with or without anti CD 20 (Rituximab). Major organ damage (eg: cerebritis, nephritis, pulmonary, cardiac or skin vasculitis) is present despite optimal immunosuppression.
- •3. Multiple Sclerosis (MS):
- •I. Diagnosis of relapsing remitting MS (RRMS) made by a Neurologist according to
- •the 2010 revised McDonald’s criteria
- •II EDSS score 0-6.5 NB: EDSS of 6.5 (this corresponds to able to walk, needing at most bilateral assistance to walk 20m without resting). Patients with an EDSS of 0-2 will require a second independent physician to assess the patient’s suitability for HSCT
- •III Disease duration of at least 15 years from diagnosis of MS
- •IV New MRI activity within last 12 months: Inflammatory active MS as defined by at least 1 Gd+ (>3mm) lesion (off steroids for one month) or at least 2 new T2 lesions on MRI within the last 12 months, compared to a reference scan not older than 36 months and preferably within the last 24 months from the date of eligibility review OR
- •a history of highly active disease, as determined by previous MRI prior to commencement of high efficacy treatment (alemtuzumab and/or natalizumab), in patients where the long term immunosuppresive risk on treatment is determined to be of significance to patients morbidity/mortality (long term risk of infection, malignancy or organ failure secondary to treatment). Confirmation regarding suitability for HSCT from an external neurologist will be required in this case.
- •V Relapsing-remitting MS (RRMS), wh
排除标准
- •- If specific auto immune disorders does not meet the individual eligibility criteria.
- •- Any patient on the study treatment arm deemed not suitable for transplant by HSCT specialist
- •- Any patient unable to understand the purpose and risks of the study
- •- Patients deemed by their treating neurologist to have entered phase of secondary progressive
研究者
相似试验
招募中
2 期
A single center Phase II study for the safety and efficacy of upfront high dose chemotherapy with thiotepa and busulfan followed by autologous peripheral blood stem cell transplantation for primary central nervous system lymphoma.JPRN-UMIN000041182Ogaki municipal hospital10
进行中（未招募）
2 期
A multi center, phase 2 study to Evaluate safety and efficacy of total Neoadjuvant treatment of long courSE radiotherapy followed by cheMotherapy, capecitaBine combined with oxaliplatin (CAPOX) for Locally advanced rEctal cancer(ENSEMBLE-2)JPRN-jRCTs071210143KAGAWA Yoshinori27
招募中
2 期
A study of clofarabine combination therapy for infant AJPRN-jRCTs041190043Miyamura Takako42
招募中
1 期
Peptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-000801-28-ITCellerys AG142
招募中
1 期
Peptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisEUCTR2022-000801-28-DECellerys AG142